Press Releases
Public Relations: Andrew Noble
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
DNAnexus and Panomics Join Forces to Deliver Comprehensive, Interactive Multi-omics Data Solutions for Biopharma Organizations
Researchers can conduct large-scale transcriptomics and proteomics data analyses on secure, cloud-based platform to accelerate biomarker discovery and drug repurposing applications.
DNAnexus Wins BioTech Breakthrough Award For BioInformatics Solution of the Year
Annual Awards Program Recognizes Innovation in the Global Life Science and Biotechnology Industries.
DNAnexus Strengthens Leadership Team to Drive Ongoing Product Innovation and Commercial Growth
Company appoints healthcare technology industry veterans Nupura Kolwalkar as Chief Product Officer and Bill Madigan as Chief Commercial Officer.
DNAnexus and Galatea Bio Launch Collaboration to Enhance Precision Medicine with Advanced Genetic Tools for Underserved Populations
Under the new agreement, Galatea Bio will use DNAnexus' Precision Health Data Cloud to increase the availability and speed of the analysis of its diverse non-European datasets. Importantly, this collaboration will allow DNAnexus' extensive network of more than 48,000 users across 48 countries to potentially leverage Galatea’s advanced local ancestry and ancestry-adjusted PRS (polygenic risk score) algorithms.
News
The Rise and Importance of Population-Scale Genome Programs
With the wealth of population-scale projects going on, we have entered a golden age of genomics. Based on efforts such as the All of Us program in the U.S. and the UK Biobank, among many others, we are poised to discover more than we ever knew about natural genetic diversity, what’s considered “normal” human biology, and the continuum of health and disease.
World’s largest genetic project opens the door to new era for treatments and cures: UK Biobank’s major milestone
In a momentous landmark for medical research, UK Biobank has today unveiled incredible new data from whole genome sequencing of its half a million participants. This is set to drive the discovery of new diagnostics, treatments and cures and, uniquely, is available to approved researchers worldwide, via a protected database containing only de-identified data (e.g. name, address, date of birth, name of GP and more stripped out).
DNAnexus included in Fast Company's 10 most innovative biotech companies of 2023
Among the 2023 Most Innovative Companies in Biotech, Fast Company is recognizing breakthroughs in DNA sequencing and spatial transcriptomics, along with innovations in biological-specimen sourcing, cell-separation technology, and the production of synthetic antibodies.